Clinical Efficacy of Recombinant Human Interferon α2b Combined with Ambroxol in the Treatment of Bronchopneumonia in Children
Objective To explore clinical efficacy of recombinant human interferon α2b(RH-INFα2b)combined with ambroxol in the treatment of bronchopneumonia in children.Methods 64 children with bronchopneumonia admitted to the hospital from March 2022 to March 2023 were selected as the research subjects.They were randomly divided into a control group and an experimental group using a random number table method,with 32 cases in each group.The control group was treated with ambroxol,while the experimental group was treated with RH-INFα2b combined with ambroxol treatment.Compare the clinical efficacy,symptom resolution time,serum inflammatory factor levels,and incidence of adverse reactions between two groups.Results The total effective rate of the experimental group was 93.75%,higher than 71.88%of the control group,and the difference was statistically significant(P＜0.05).The disappearance time of cough,shortness of breath,lung moist rales,and fever in the experimental group were shorter than those in the control group,and the differences between the groups were statistically significant(P＜0.05).After treatment,the average levels of transforming growth factor,C-reactive protein,and calcitonin in the experimental group were lower than those in the control group,with statistically significant differences between the groups(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion The combination of RH-INFα2b and ambroxol has a significant effect on treating children with bronchopneumonia,which is beneficial for shortening the time of symptom resolution,improving cytokine levels in children,and has high safety.It is worth promoting and applying.
BronchopneumoniaRecombinant human interferon α2bAmbroxolSymptom resolution time
NETL
NSTL
万方数据
